Christopher Cannon/LinkedIn
Oct 3, 2025, 11:50
Christopher Cannon on Evolocumab – Landmark Phase 3 Trial Shows Benefit in Those at High Risk of CV Events
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared on LinkedIn:
”Late-breaking news!!!
PCSK9 inhibition with evolocumab shows benefit in those at high risk of CV events, (in addition to secondary prevention as shown in FOURIER)”
Read the full article here.
Article: Landmark Phase 3 Trial (Vesalius-CV) Meets Primary Endpoints in a Cardiovascular Primary Prevention Study of 12,000 Patients

Stay updated on the latest scientific breakthroughs with Hemostasis Today.
-
Nov 19, 2026, 05:54Global Collaboration in Hemostasis – ISTH
-
Nov 19, 2026, 05:40Pete Stibbs: Advancing Treatment Strategies in Venous Disease
-
Nov 19, 2026, 05:31Lance Reed: One Donation, Multiple Lives
-
Nov 19, 2026, 05:20ZPI Silencing as a Novel Non-Factor Therapy for Rare Bleeding Disorders – HITh
-
Nov 19, 2026, 04:48Antiphospholipid Antibodies and Stroke Management – RPTH
-
Nov 18, 2026, 20:58Uma Vaidyanathan: When Hemoglobin Does Not Respond to Iron Therapy, Look Beyond Iron Deficiency
-
Nov 18, 2026, 20:57Jamil Rafiq: 5 Ways to Prevent Sample Haemolysis
-
Nov 18, 2026, 20:55Nasir Jamal: Plasmapheresis – Key Concepts at a Glance
-
Nov 18, 2026, 20:55Tarık Seller: Pulmonary Embolism – When a Blood Clot Becomes a Life-Threatening Emergency